These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34289585)

  • 21. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.
    Huang K; Mo Q; Liao C; Feng S; Liu G; Jiang D; Lei P
    Clin Exp Med; 2024 May; 24(1):107. PubMed ID: 38776019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
    Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
    Sobas M; Kiladjian JJ; Beauverd Y; Curto-Garcia N; Sadjadian P; Shih LY; Devos T; Krochmalczyk D; Galli S; Bieniaszewska M; Seferynska I; McMullin MF; Armatys A; Spalek A; Waclaw J; Zdrenghea M; Legros L; Girodon F; Lewandowski K; Angona Figueras A; Samuelsson J; Abuin Blanco A; Cony-Makhoul P; Collins A; James C; Kusec R; Lauermannova M; Noya MS; Skowronek M; Szukalski L; Szmigielska-Kaplon A; Wondergem M; Dudchenko I; Gora Tybor J; Laribi K; Kulikowska de Nalecz A; Demory JL; Le Du K; Zweegman S; Besses Raebel C; Skoda R; Giraudier S; Griesshammer M; Harrison CN; Ianotto JC
    Blood Adv; 2022 Sep; 6(17):5171-5183. PubMed ID: 35802458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
    Hur JY; Choi N; Choi JH; Kim J; Won YW
    Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
    Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges.
    Tiu A; Chiasakul T; Kessler CM
    Semin Thromb Hemost; 2024 Mar; 50(2):213-223. PubMed ID: 37068511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital.
    Sukrisman L
    J Blood Med; 2022; 13():495-503. PubMed ID: 36118738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocytosis and MPNs: Where do we stand?
    Coltoff A
    Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
    Pemmaraju N; Gerds AT; Yu J; Parasuraman S; Shah A; Xi A; Kumar S; Scherber RM; Verstovsek S
    Leuk Res; 2022 Apr; 115():106809. PubMed ID: 35220060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update from the latest WHO classification of MPNs: a user's manual.
    Passamonti F; Maffioli M
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):534-542. PubMed ID: 27913526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
    Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
    Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
    Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.